Dec 18 (Reuters) - Krystal Biotech Inc KRYS.O:
KRYSTAL BIOTECH ANNOUNCES EARLY EVIDENCE OF MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
REPORTS 27% ORR AND 73% DCR IN NSCLC TRIAL
MAJORITY OF TREATMENT-RELATED ADVERSE EVENTS BEEN MILD TO MODERATE IN SEVERITY & TRANSIENT, WITH NO GRADE 4 OR 5 ADVERSE EVENTS OBSERVED
Source text: ID:nGNX3mDtjH
Further company coverage: KRYS.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。